Published on: 13 April 2023
Theramex, in agreement with the MHRA, has issued a direct healthcare professional communications (DHPC) letter relating to prescribing of Zoely®, a combined oral contraceptive containing estradiol in combination with 2.5mg of the progestogen nomegestrol acetate (NOMAC).
The guidance is a response to evidence indicating an association between use of preparations containing nomegestrol acetate at higher doses than in Zoely (3.75mg-5mg) and increased risk of intracranial meningioma.
There is not evidence relating directly to use of Zoely itself.
Your download should start automatically. If not download directly.